Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $93.33 Consensus Target Price from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $93.33.

PBH has been the topic of several analyst reports. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. StockNews.com cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, April 8th. Oppenheimer increased their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Canaccord Genuity Group lifted their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Finally, DA Davidson increased their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th.

Insider Activity

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now owns 17,157 shares of the company’s stock, valued at $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. raised its position in Prestige Consumer Healthcare by 3.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock valued at $19,630,000 after purchasing an additional 8,533 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after buying an additional 50,961 shares during the period. Avior Wealth Management LLC grew its holdings in shares of Prestige Consumer Healthcare by 1,570.7% during the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock worth $668,000 after buying an additional 8,042 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Prestige Consumer Healthcare by 5.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock valued at $49,667,000 after acquiring an additional 33,844 shares during the period. Finally, Norges Bank purchased a new stake in Prestige Consumer Healthcare during the 4th quarter valued at approximately $40,009,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $80.10 on Friday. The company’s 50 day moving average is $84.27 and its two-hundred day moving average is $80.03. The firm has a market cap of $3.97 billion, a PE ratio of 18.76, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare has a 52-week low of $62.35 and a 52-week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, research analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.